Articles tagged with Antibody Therapy
Researchers at Karolinska Institutet have conducted a Phase 2 UNITY clinical trial involving pregnant women with a history of very severe HDFN. Nipocalimab was found to prevent and mitigate the disease without causing serious side effects in the mother or fetus.
A clinical study in Birmingham has found that nipocalimab can improve the survival rate of unborn babies with rare fetal anaemia. The majority of pregnant patients who received nipocalimab gave birth at or after 32 weeks without needing an intrauterine transfusion, resulting in a perinatal survival rate of 92%.
Researchers found that children's immune systems attacked their own tissues after latching onto a coronavirus protein resembling one found in multiple organs. Early intervention was crucial to prevent death in these cases, and the study has implications for understanding other autoimmune diseases.
A new study found that subclinical hypothyroidism diagnosed before 21 weeks of pregnancy is associated with higher rates of overt hypothyroidism or thyroid replacement therapy within 5 years after delivery. Women with high TSH values and elevated TPO antibodies were at increased risk.
Researchers have developed a technique to edit B cells to produce custom antibodies, opening up new possibilities for treating chronic conditions. The technology uses CRISPR gene editing to reprogram B cells as biofactories making custom antibodies.
A new study reveals that about two percent of the population develop autoantibodies against type 1 interferons, making them more susceptible to severe viral infections. The autoantibodies remain detectable in the blood for life and are associated with a compromised type 1 interferon system.
Researchers discuss HER2 in breast cancer, highlighting the prognostic and predictive factors. They found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer, challenging the long-held view that HER2-negative tumors do not benefit from trastuzumab-based therapy.
A study has identified a key factor in how SARS-CoV-2 evades the immune system, which could lead to effective treatments. The researchers discovered that the virus distorts certain proteins on infected cells to inhibit interaction with T-lymphocytes, facilitating viral proliferation.
Researchers discuss the use of antibody-drug conjugates (ADCs) in treating biologically aggressive tumors, such as uterine serous carcinoma. The ADC T-DXd has shown remarkable preclinical activity against primary USC cells lines and xenografts overexpressing HER2/neu.
Researchers discovered that co-administering two anti-CADM1 antibodies, 3E1 and 9D2, enhances tumor suppression by relocating CADM1 proteins to stable cellular structures. This relocation triggers endocytosis, leading to increased drug uptake by cancer cells.
Researchers have developed a humanized mouse model with a fully functional human immune system, enabling the study of immunotherapy development, disease modeling, and vaccine development. The new model, called TruHuX, mounts specific antibody responses and can develop full-fledged systemic lupus autoimmunity.
A study published in PNAS reveals that ETV5 enhances the expression of osteopontin, leading to the differentiation of T cells into follicular helper cells. In SLE patients, disease activity is proportional to ETV5 and osteopontin levels, suggesting a potential therapeutic target for treating lupus.
Researchers have discovered how a neutralizing antibody blocks measles virus infection by arresting the fusion process. The study's findings may also be relevant to other viruses with pandemic potential, such as Nipah and parainfluenza viruses.
Researchers at Johns Hopkins Medicine identified a potentially new biological target involving Aplp1, which drives the spread of Parkinson's disease-causing alpha-synuclein. The findings suggest targeting this interaction with drugs could slow Parkinson's disease progression and other neurodegenerative diseases.
A new trial indicates that immunotherapy could successfully treat the most common form of colorectal cancer. The study, published in Nature Medicine, found that botensilimab and balstilimab caused tumours to shrink or remain stable in 61% of patients with microsatellite stable metastatic colorectal cancer.
Researchers at Brigham and Women's Hospital have developed a new nanomedicine therapy that delivers anticancer drugs to lung cancer cells and enhances the immune system's ability to fight cancer. The therapy shows promising results in cancer cells in the lab and in mouse lung tumor models, with potential applications for improving care...
Researchers developed Epitope Binning-seq to analyze epitopes in monoclonal antibodies. The method accurately classified antibodies into distinct epitope bins, providing valuable insights into their binding patterns and streamlining early antibody drug development.
Researchers developed a novel immunotherapy approach using ultrasound to deliver chemotherapy and antibodies to the brain, boosting immune system recognition of glioblastoma cells. The treatment showed promise in improving responses to PD-1 blockade in patients with advanced brain tumors.
The first phase 1 trial of the bispecific antibody FS222 demonstrates promising antitumour activity, especially in patients with metastatic cutaneous melanoma refractory to immunotherapy. Preliminary results show partial or complete objective response rates in various tumor types.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Researchers developed a novel approach to block cancer cell growth by targeting specific proteins, reducing side effects and increasing treatment efficacy. The method uses antibody-peptide inhibitor conjugates, which deliver inhibitors specifically to cancer cells,
Quadruple therapies offer deeper responses and longer clinical benefits for patients with newly diagnosed multiple myeloma. The addition of an immunotherapy agent to the backbone of small molecule drugs may improve overall survival and reduce the need for bone marrow transplants.
A study found that moderate-to-vigorous exercise bouts increased natural killer cells' ability to kill cancer cells and made them more susceptible to antibody therapy. This could hold promise for improving treatment outcomes for some forms of chronic lymphocytic leukemia. Further research is needed to confirm these findings.
A new study published in Nature Biomedical Engineering shows that targeted cancer treatment using antibody-displaying extracellular vesicles reduces tumour growth and improves survival in mice. The treatment has the potential to be used against other diseases and cancer types, offering a more effective and fewer side effects compared t...
A nanosystem combining a branched glycopolymer prodrug-derived nanoassembly with a STING agonist increases matured dendritic cells and CD8+ T cells, promoting an immuno-supportive microenvironment. This enhances the therapy effect of anti-PD-L1 antibodies in breast and colon tumor mice.
Researchers developed a synthetic biomarker technology that can differentiate between prior Zika and dengue virus infections. The technology, using epitope surrogates, correctly identified people previously infected with Zika virus 85.3% of the time.
A third Covid vaccine dose has been shown to improve defensive antibody responses in some clinically extremely vulnerable patients. The trial found that 90% of patients who received a booster dose developed significant antibodies, but more than half of those with low initial responses saw no improvement.
A team of scientists has developed a novel vaccine approach that induces long-lasting protective immunity against SARS-CoV-2 virus in pre-clinical models. The Clec9A-RBD antibody construct targets specific dendritic cells, leading to exceptional durability of immune responses and potential to address shortcoming of current mRNA vaccines.
A mid-stage trial of an experimental malaria monoclonal antibody found it to be 77% effective in preventing infection and disease in children in Mali. The treatment, administered by subcutaneous injection, was developed by the National Institutes of Health (NIH) and is designed to provide long-acting protection against malaria.
A new study published in the Journal of Clinical Oncology identified NECTIN4 amplification as a potential genomic biomarker for predicting treatment response to enfortumab vedotin in patients with advanced urothelial carcinoma. The study found that over 90% of patients with NECTIN4 amplification showed tumor response to EV therapy.
Researchers developed novel therapeutic bispecific antibodies targeting IgM and B-cell surface antigens, which directly inhibited cell proliferation via cell-cycle arrest and apoptosis in vitro. These findings suggest that anti-IgM/B-cell surface antigen-binding specific antibodies are promising therapeutic agents for B-cell malignancies.
Researchers identified how AML cells develop resistance to first-line treatments by up-regulating multiple signalling pathways. Targeting RAS family proteins shuts off this route, preventing cancer cell death.
Researchers at WashU Medicine have found a new way to remove toxic amyloid plaques from the brain using an antibody that activates microglia. This approach has implications beyond Alzheimer's disease and could potentially clear other neurodegenerative conditions.
Researchers at UVA Health discovered a potential explanation for long COVID symptoms by identifying 'abzymes' that act like enzymes regulating important bodily functions. This discovery could lead to new treatments targeting these rogue antibodies to alleviate acute effects of COVID-19 and its complications.
Scientists at The Florey have developed an mRNA technology approach to target the toxic protein tau, which builds up in patients with Alzheimer’s disease and other dementias. This new method demonstrates that mRNA can serve purposes other than vaccine development, offering a promising alternative to conventional treatments.
A study published in Immunity identified key findings from a patient who cleared hepatitis C, revealing new insights into the development of a vaccine. The researchers found that this individual's antibodies targeted multiple regions of the virus, suggesting a potential approach to elicit a stronger immune response.
Researchers investigated the role of long-lived plasma cells in COVID-19 infection, finding deficient generation of spike-specific antibodies. The study suggests that inadequate long-lived plasma cell production may be responsible for short-lived protective antibody responses to SARS-CoV-2.
Researchers at Leibniz-HKI deciphered the function of Candidalysin's unusual protein structure, which reduces pathogenicity and opens up new treatment options. Nanobodies neutralize the toxin, blocking its activity and inhibiting tissue damage.
Researchers have made progress in understanding atherosclerosis, identifying potential new approaches for early detection and therapy. The study found that TREM2 regulates the activity of macrophages, playing an important role in forming unstable plaques that increase heart attack and stroke risk.
Researchers discover that certain bacteria can evade the immune system by circumventing antibody coating, leading to severe inflammation. The study identifies IgG2 as a key player in this process, providing potential biomarkers and targets for new treatments.
The study reveals that LAG-3 exists as a dimer, with two molecules forming the functional checkpoint protein. An antibody used to demonstrate therapeutic efficacy in animal models blocks activity by binding to the dimer interface. This new understanding may lead to better cancer treatments targeting this protein.
A recent study found that newer monovalent COVID vaccines generated higher levels of antibodies against a range of Omicron variants, including the XBB and BQ.1.1 strains. The researchers also discovered that these vaccines increased mucosal antibody production, but not neutralizing antibody levels in the nasal cavity.
A new tool using electrocatalysis enables precise modification of site-specifically incorporated 5-hydroxytryptophan residues on many different proteins, including full-length therapeutic antibodies. The eCLIC method has potential applications in developing novel biotherapeutics and protein-based research tools.
A novel antibody constant region variant (REW) extends plasma half-life and improves biodistribution, allowing for both invasive and non-invasive delivery. The REW technology also enhances the complement system, providing enhanced ability to kill cancer cells and bacteria.
A combination of CS1002 and CS1003 showed promising anti-tumor activity and a manageable safety profile across various dosing ranges in patients with advanced solid tumors. The treatment was found to be effective in certain types of cancers, including melanoma and skin cancer.
A monoclonal antibody, omalizumab, increased the tolerance threshold for multiple food allergens, allowing children to consume larger amounts without a reaction. The treatment showed significant benefits in reducing allergic reactions, particularly for peanut and egg, with potential protection against accidental exposure.
A new strategy used by cancer cells to protect themselves from immune system attack has been identified, and a potential target for immunotherapy has been found. Blocking activin receptor 1C on CD4+ T cells may help prevent the accumulation of immune-suppressing Tregs in tumors and slow tumor growth.
Researchers at Dartmouth's Geisel School of Medicine and Thayer School of Engineering have made significant breakthroughs in understanding how antibodies combat herpes simplex virus (HSV) infections. The study reveals that antibody effector functions play a critical role in protecting against HSV, which may lead to new treatments for n...
Researchers at Rice University have discovered a promising new immunological pathway to treat stubborn bone tumors in breast cancer patients. The glyco-immune checkpoint axis, involving protein Siglec-15, plays a crucial role in hiding bone tumors from the immune system.
A groundbreaking study identifies FAM3C as a key regulator of breast cancer progression within the tumor microenvironment. The overexpression of FAM3C promotes breast cancer cell survival and metastasis, while its depletion inhibits tumor growth in genetically engineered mouse models.
A new study published in Oncogene highlights the effectiveness of MDX-124, a therapeutic drug targeting annexin-A1, which promotes tumour progression. High annexin-A1 expression levels correlate with poorer overall survival in various cancers.
Researchers from Osaka University have discovered a novel treatment strategy for cytokine storm, a serious inflammatory syndrome triggered by an infection or severe burn. The new approach involves blocking IL-6 receptor signaling with a short-term antibody, minimizing treatment side effects and preventing vascular damage.
Researchers from Tokyo University of Science discovered that manipulating polyamines enhances the functional profiles of monoclonal antibodies. The study found that controlling polyamine levels increases IgG galactosylation, leading to improved therapeutic efficacy.
Researchers have found that antibody sequences contain an unusual number of codons without corresponding tRNAs, which can be bridged by the inosine wobble modification. This modification allows for more efficient production of antibodies, with implications for vaccine efficacy and rationally designed vaccines.
Researchers at Karolinska Institutet have developed a nasal spray with IgA antibodies that can protect mice from SARS-CoV-2 infection. The treatment significantly diminished virus load in infected mice and showed stronger binding to the spike protein compared to original IgG antibodies.
Cancer immunotherapy can cause severe colitis due to hyper-activated immune T cells and deleted regulatory T cells. Researchers at Michigan Medicine have identified a new mouse model that develops colitis after treatment with antibodies used for tumor immunotherapy, revealing the mechanism behind this side effect.
Researchers developed a novel platform to transport therapeutic antibodies across the blood-brain barrier using a biocompatible polymer. The method showed promising results in both in vitro and mouse-model experiments, suggesting enhanced brain delivery of cancer-fighting antibodies without inducing adverse effects.
Researchers at Kobe University developed a new model of mice with humanized immune systems to test anti-cancer drugs targeting the immune system. The study showed that a therapy blindfolding immune cells to self-recognition can activate them to attack tumor cells, promoting an effective cancer response.
Researchers have identified promising treatment candidates for morphine tolerance and cancer, as well as a biomarker for kidney injury. A monoclonal antibody targeting the mu-opioid receptor has been shown to alleviate morphine tolerance and physical dependence, while inducing excessive mitochondrial fission in tumor cells. Additionall...
A comprehensive review of targeted therapies for lupus nephritis discusses the challenges of current treatments and proposes strategies to overcome obstacles. Recent advancements in B-cell targeting and alternative approaches such as CAR-T cells are highlighted.